185 related articles for article (PubMed ID: 38715693)
1. Neurofilament light chain as a biomarker for acute hepatic porphyrias.
Sgobbi P; Serrano PL; Badia BML; Farias IB; de Oliveira HB; Barbosa AS; Pereira CA; Moreira VF; Pinto ÍFN; Oliveira ASB; Pinto WBVR
Front Neurol; 2024; 15():1384678. PubMed ID: 38715693
[TBL] [Abstract][Full Text] [Related]
2. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
Wang B; Bonkovsky HL; Lim JK; Balwani M
Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
[TBL] [Abstract][Full Text] [Related]
3. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M
Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858
[TBL] [Abstract][Full Text] [Related]
4. Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels.
Agarwal S; Habtemarium B; Xu Y; Simon AR; Kim JB; Robbie GJ
JIMD Rep; 2021 Jan; 57(1):85-93. PubMed ID: 33473344
[TBL] [Abstract][Full Text] [Related]
5. Patient Perspective on Acute Hepatic Porphyria with Sporadic Attacks: A Chronic Disease with Substantial Health-Related Quality of Life Impacts.
Wheeden K; Lyon Howe D; Burrell S; Gill L; Chamberlayne J; Williams ER; Simon A; Ko JJ; Mora J; Wells T; Evans C; Paulich M; Meninger S; Lombardelli S
Adv Ther; 2022 Sep; 39(9):4330-4345. PubMed ID: 35907153
[TBL] [Abstract][Full Text] [Related]
6. The acute hepatic porphyrias.
Wang B
Transl Gastroenterol Hepatol; 2021; 6():24. PubMed ID: 33824928
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study.
Horie Y; Yasuoka Y; Adachi T
Orphanet J Rare Dis; 2023 Dec; 18(1):384. PubMed ID: 38066651
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
Kuter DJ; Bonkovsky HL; Monroy S; Ross G; Guillén-Navarro E; Cappellini MD; Minder AE; Hother-Nielsen O; Ventura P; Jia G; Sweetser MT; Thapar M;
J Hepatol; 2023 Nov; 79(5):1150-1158. PubMed ID: 37479139
[TBL] [Abstract][Full Text] [Related]
9. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
Sardh E; Harper P
J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
[TBL] [Abstract][Full Text] [Related]
10. Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians.
Anderson KE; Lobo R; Salazar D; Schloetter M; Spitzer G; White AL; Young RM; Bonkovsky HL; Frank EL; Mora J; Tortorelli S
Am J Med Sci; 2021 Aug; 362(2):113-121. PubMed ID: 33865828
[TBL] [Abstract][Full Text] [Related]
11. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.
Marcacci M; Ricci A; Cuoghi C; Marchini S; Pietrangelo A; Ventura P
Orphanet J Rare Dis; 2022 Apr; 17(1):160. PubMed ID: 35392955
[TBL] [Abstract][Full Text] [Related]
12. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
[TBL] [Abstract][Full Text] [Related]
13. Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals.
Lissing M; Vassiliou D; Floderus Y; Harper P; Bottai M; Kotopouli M; Hagström H; Sardh E; Wahlin S
J Intern Med; 2022 Jun; 291(6):824-836. PubMed ID: 35112415
[TBL] [Abstract][Full Text] [Related]
14. Acute Hepatic Porphyrias: "Purple Flags"-Clinical Features That Should Prompt Specific Diagnostic Testing.
Anderson KE; Desnick RJ; Stewart MF; Ventura P; Bonkovsky HL
Am J Med Sci; 2022 Jan; 363(1):1-10. PubMed ID: 34606756
[TBL] [Abstract][Full Text] [Related]
15. Brazilian registry of patients with porphyria: REBRAPPO study.
Souza PVS; Afonso G; de Rezende Pinto WBV; de Lima Serrano P; de Mattos Lombardi Badia B; Farias IB; Dos Santos Jorge AC; Machado RIL; Pinto IFN; Barros GB; de Oliveira HB; Calil SR; Franz C; Oliveira ASB
Orphanet J Rare Dis; 2023 Mar; 18(1):49. PubMed ID: 36890577
[TBL] [Abstract][Full Text] [Related]
16. Novel treatment options for acute hepatic porphyrias.
Wang B
Curr Opin Gastroenterol; 2021 May; 37(3):194-199. PubMed ID: 33769375
[TBL] [Abstract][Full Text] [Related]
17. Detecting rare diseases in electronic health records using machine learning and knowledge engineering: Case study of acute hepatic porphyria.
Cohen AM; Chamberlin S; Deloughery T; Nguyen M; Bedrick S; Meninger S; Ko JJ; Amin JJ; Wei AJ; Hersh W
PLoS One; 2020; 15(7):e0235574. PubMed ID: 32614911
[TBL] [Abstract][Full Text] [Related]
18. Expert consensus statement on acute hepatic porphyria in Belgium.
Gilles A; Vermeersch S; Vermeersch P; Wolff F; Cotton F; Tilleux S; Cassiman D
Acta Clin Belg; 2022 Aug; 77(4):735-741. PubMed ID: 34369323
[TBL] [Abstract][Full Text] [Related]
19. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?
Romano A; Primiano G; Antonini G; Ceccanti M; Fenu S; Forcina F; Gentile L; Inghilleri M; Leonardi L; Manganelli F; Obici L; Sabino A; Sciarrone MA; Tozza S; Vitali F; Luigetti M
Eur J Neurol; 2024 Jan; 31(1):e16070. PubMed ID: 37724995
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
